It is well-established that the HIV-1 envelope glycoprotein surface unit, gp120, binds to cell-associated heparan sulfate (HS). Virus infectivity is increased by such interaction and a variety of soluble polyanions efficiently neutralize HIV-1 in vitro. This interaction has been mainly attributed to the gp120 V3 loop. However, although a number of evidence suggested that this particular domain does not fully recapitulate the binding activity of the protein, the ability of HS to bind to other regions of gp120 has not been completely addressed, and the exact localizations of the polysaccharide binding sites are not known. To investigate in more detail the structural basis of the HS-gp120 interaction, we used a mapping strategy, and compared the heparin binding activity of wild type and mutant gp120, using surface plasmon resonance based binding assays. 
INTRODUCTION

Human immunodeficiency virus (HIV) gains entry into permissive CD4
+ cells by sequentially interacting with CD4, the primary receptor, and a coreceptor, usually either CCR5 or CXCR4 (1) . Both receptor and coreceptors are recognized by gp120, the glycoprotein which constitutes the surface unit of HIV envelope spikes. This protein consists of five relatively conserved regions (C1 to C5), that fold into a "core" comprising two distinct domains termed "inner" and "outer", and five variable regions (V1 to V5). This protein is prone to structural changes and is believed to sample a number of different conformations. A wealth of evidence showed that upon binding to CD4, roughly half of the gp120 core structure undergoes structural rearrangements, in particular within the inner domain. In the CD4 bound form, the base of the V1/V2 region of the inner domain (β2 and β3 strands) is brought to close proximity to a β-hairpin of the outer domain (β20 and β21 strands) and forms a four-stranded β-sheet located within the bridging sheet that connects the inner and the outer domain of the glycoprotein. Importantly this highly conserved structure forms, in conjunction with the V3 loop, the binding site for CCR5 or CXCR4 (2-7). It has been well known that HIV also binds to CD4 -cells, in a gp120 dependent manner, through interactions with cell surface molecules, including heparan sulfates (HS) (8) . HS, and the closely related heparin, belong to a large family of anionic polysaccharides, collectively known as glycosaminoglycans. They occur covalently bound to core proteins and are ubiquitously expressed at most cell surfaces (9) . These molecules are structurally complex, characterized by very large interactive properties and recognize many unrelated protein via clusters of basic amino acids exposed on the surface of their targets (10) . As such, they are exploited as a prevalent source of docking sites by a large array of pathogens (11) (12) (13) that interact with highly sulfated heparin-like regions of these polysaccharide (14) . Regarding HIV, it has been early described that removal of HS from the cell membrane inhibited infection, by reducing viral particle concentration at the cell surface (15) . It is now however appreciated that HIV binding to HS can occur at many places and serves many functions. At the mucosal surface, the main point of entry for the virus into the host, HS sequester viral particles and are involved in their translocation across epithelial barriers (16) (17) (18) . Similarly, HS expressed by microvasculature endothelial cells of the blood brain barrier capture HIV and contribute to HIV brain invasion (19) (20) (21) . Several studies also showed that HS play an active role in sequestering, protecting and transferring viruses to CD4 + susceptible cells, with conditions that boost their replication (in trans mechanism) (22, 23) . On permissive cells, HIV binding to HS is thought to increase infectivity by favoring viral particle concentration at the cell surface (in cis process). For some cells, such as macrophages, they may compensate for low CD4 expression (24) . It has also been suggested that HS could be directly involved in the infection of CD4 -cells, including endothelial cells and possibly neurons (19, 25) . Finally, HS and heparin have been found to inhibit the protein disulfide isomerase-mediated reduction of gp120, although the exact role of this effect has not been elucidated yet (26) . In addition to mediating viral attachment and entry, gp120 (either free or virion associated), targets a number of uninfected or non permissive cells. As such, it is involved in some aspects of the AIDS-associated pathologies, including apoptosis and oxidative stress, and this has motivated the development of heparinmimetics that inhibit gp120-HS interactions (27) . A large body of work, aiming at characterizing the gp120/HS complex, showed that heparin, HS or other polyanions including dextran sulfate, bind to gp120 V3 loop derived peptides or compete with V3 loop specific monoclonal antibodies (mAbs) for binding to gp120 (28) (29) (30) (31) . However, this binding, which affinity (Kd # 200 nM) has been determined by surface plasmon resonance based binding assay (32), appears to be more complex than previously thought. The binding of polyanions to gp120 interferes with several mAbs recognizing epitopes outside the V3 loop, including those that target the bridging sheet induced upon CD4 binding (15, 32) . In agreement with these observations, it has been previously reported that gp120 in its CD4-bound state had a substantially increased binding activity toward heparin, compared to free gp120, and molecular modeling further suggested that the bridging sheet includes a possible HS binding domain (HBD) (33) . Finally, it has also been demonstrated that the development of resistance to dextran sulfate correlates with specific mutations within and outside the V3 loop (34) . Through an approach designed to simultaneously map different HBDs at the protein surface and the production of gp120 mutants, the present work identified the presence of four HBDs on the glycoprotein, some of which being potential targets for therapeutic applications.
MATERIAL AND METHODS
Material
Insect cell culture media and the Bac-to-Bac system were purchased from Invitrogen (Carlsbad, CA -USA) and the QuickChange TM site-directed mutagenesis kit from Stratagene (La Jolla, CA -USA). SP sepharose Fast Flow resin, Lentil-lectin resin, Superdex 200 column, EDC/NHS reagents and all SPR products were supplied from GE Healthcare (Chalfont St. Giles -UK). DEAE Sephacel resin, 15 kDa heparin, 6 kDa heparin and thermolysin were from Sigma Aldrich (St Louis, MO -USA). Heparin derived dodecasaccharide (dp12) was prepared as described (35) . The ultrafiltration unit and membranes were purchased from Millipore (Billerica, MA -USA). Recombinant soluble CD4 (sCD4) was from Progenics Pharmaceuticals (Tarrytown, NY -USA) and obtained through the NIH AIDS Research and Reference Reagent Program. Monoclonal antibody 17b was from the Centre for AIDS Reagent Program, National Institute for Biological Standards and Control.
Recombinant wild type and mutant proteins production
The cDNA encoding gp120 HXBc2 , was amplified by PCR from pSVIII-env and inserted into pNT-Bac, encoding either the melittin or the baculovirus ecdysteroid UDP glucosyltransferase signal peptide, using the BamH I and Hind III restriction sites. Mutations to give rise to gp120-K121S, gp120-R419S, gp120-K421S and gp120-K432S were introduced using the QuickChange TM site- 
Protein purification
For large-scale protein production, Sf21 cells were adapted for growth in suspension. Sf21 cells (1 L at 0.5 × 10 6 cells/mL) were infected for 72 h with recombinant viruses at a MOI of 8, in Sf900 II SFM medium. Purification of both wild-type and mutant proteins was performed at 4°C using a three-step method. The supernatant (1 L) was injected into a SPSepharose Fast Flow cation-exchange Column (XK16) equilibrated with 50 mM of HEPES pH 8.2 (solvent A), at a flow rate of 2 mL/min. The column was washed with five column volumes of A and five column volumes of A supplemented with 0,3% surfactant P20 (GE Healthcare). Elution was performed using a two-step NaCl gradient (from 0 to 0.5 M NaCl in 12 mins and 0.5 to 1 M NaCl in 2 mins) and monitored by absorbance (280 nm). Fractions containing gp120 were pooled and loaded onto a Lentil lectin sepharose column (1.6 x 10 cm) pre-equilibrated with Phosphate-Buffered Saline (PBS), at 1 mL/min. The column was washed with 30 mL of PBS and bound proteins were eluted with PBS containing 1 M Methyl-α-D-mannopyranoside. Fractions (0.5 ml) containing gp120 were pooled and concentrated by ultrafiltration, using an Amicon 8010 Filter unit fitted with a YM30 ultrafiltration membrane (30 000 MWCO), followed by concentration on a microcon unit (10 000 MWCO). The sample was then size fractionated onto a Superdex 200 HR 10/30 column equilibrated with PBS, at 0.4 mL/min. Fractions (0.5 mL) containing gp120 were concentrated and quantified by amino acid analysis. Protease inhibitors (CompleteRoche) were added and the sample was stored at -20°C. Throughout the procedure, fractions were monitored by absorbance (280 nm) and analyzed by SDS-PAGE stained with coomassie blue and Western blotting, as described above.
Surface plasmon resonance (SPR)-based binding assays SPR (BIAcore 3000) instrument was used to investigate the binding of wild type or mutant gp120 to immobilized CD4, heparin or mAb 17b. For that purpose, flow cells of a CM4 sensor chip were first activated with 50 µL of 0.2 M N-ethyl-N'-(diethylaminopropyl)-carbodiimide (EDC) and 0.05 M N-hydroxysuccimide (NHS) at 5 µL/min. Then, soluble CD4 (5 µg/mL in 10 mM acetate buffer, pH 4.5), mAb 17b (5 µg/mL in 10 mM acetate buffer, pH 5) or streptavidin (100 µg/mL in 10 mM acetate buffer, pH 4.2) were injected at 5 µL/min over one of the activated flow cell until levels of 650, 500 or 2500 response units (RU) were respectively achieved. Biotinylated heparin was captured on the streptavidin surface to get a level of 25 RU. The fourth flow cell (functionalized with 2500 RU of streptavidin) served as a negative control. Samples in HBS-P (10 mM HEPES, 150 mM NaCl and 0,005% surfactant P20, pH 7.4) were injected over the different surfaces at a flow rate of 10 µL/mL, after which the formed complexes were washed with HBS-P. Surfaces were regenerated by sequential injections of 10 mM HCl (1 min) and 2 M NaCl (2.5 mins). Each binding curve was corrected for nonspecific binding by subtraction of the signal obtained from the negative-control flow cell.
Mapping of heparin/HS binding domains within gp120
Analysis of HBD was adapted from "the beads approach" previously described (37) , but performed with free heparin, in solution. Heparin (200 µg) was activated with 6 mM EDC and 15 mM NHS for 12 min, at room temperature. Reactants in excess were inactivated by the addition of β-mercaptoethanol (20 mM final) for 15 min. Gp120 (3.5 µM) was incubated with 35 µM of the activated heparin, in 100 µL of PBS, for 2 h at room temperature, then the reaction was quenched by addition of 11 µL of 1 M Tris, pH 7.5. Proteins cross linked to heparin were digested overnight with 53 mIU of thermolysin, at 60°C. Released peptides and thermolysin were removed by purification of the conjugates using weak anion exchange chromatography. Briefly, the sample was injected at 1 mL/min onto a 2 mL DEAE Sephacel column, equilibrated with 20 mM of Na 2 HPO 4 /NaH 2 PO 4 pH 6.5 (solvent A). The column was washed with five to ten column volumes of A and five to ten column volumes of A supplemented with 0.3 M NaCl. Peptideheparin conjugates were then eluted with buffer A, containing 1 M NaCl. Eluted fractions (1 mL) were analyzed by monitoring the absorbance at 280 and 232 nm. In preliminary experiments, biotinylated heparin was added in the mixture (as a tracer) and blotted fractions were analyzed using peroxidase conjugated streptavidin. Peptideheparin conjugate containing fractions were pooled, desalted onto a PD-10 column and identified by N-terminal sequencing as described (37) .
RESULTS
Time-course expression and purification of recombinant gp120 HXBc2 in Sf21 insect cells
To produce the HIV envelope glycoprotein, recombinant baculoviruses encoding wild type or mutant gp120s in frame with the melittin signal peptide, were generated and used to infect Sf21 cells. The cell medium was harvested at different times post infection and analyzed for gp120 expression by Western blotting. Immunoreactive material with a molecular mass of about 110-120 kDa was detected and migrated as purified gp120 used as a standard (Fig. 1A ). Significant expression was observed 48 h after infection, with a maximum after 72 h. Longer infection times resulted in proteolytic degradation. Infection time chosen for subsequent experiments was 72 h. In these conditions, gp120 was secreted into the culture medium at an estimated level of 25-30 mg/L. Similar amounts were produced using an expression vector, including a leader sequence derived from the baculovirus ecdysteroid UDP glucosyltransferase (data not shown).
For large scale preparation, wild-type and mutant gp120s were expressed in Sf21 cells adapted for growth in suspension. Cells were harvested 72 h after infection, centrifuged and the supernatant (1 L) was run through a SP sepharose column. The column was first washed with 30 ml of 50 mM HEPES pH 8.2 then with surfactant P20 to remove a baculovirus protein (egt) which otherwise coeluted with gp120 during the next step (data not shown). Bound proteins were then eluted with a NaCl gradient and the gp120 containing fractions injected over a Lentil-lectin column. The flow-through fractions did not contain gp120 (Fig. 1B, lane 2) , which was then eluted from the lectin column with 1 M Methyl-α -Dmannopyranoside in PBS (Fig. 1B, lane 3) . The material was further purified by gel filtration on a Superdex 200 HR column (Fig.  1B, lane 4) . Fractions containing gp120 were pooled, concentrated and stored at -20°C. Affinity chromatography on the Lentil-lectin was the most efficient purification step. Mutant proteins were purified using the same protocol and purity was estimated to be at least 90% by coomassie blue staining on SDS-PAGE (Fig.  1C) . Through out the purification procedure, only the fractions corresponding to the apex of the eluted peaks were collected to ensure maximum purity. Purified proteins were finally quantified by amino acid analysis. This three step-purification protocol enabled us to get around 1 mg of purified gp120/litre of culture medium.
CD4 binds to wild-type gp120 and triggers mAb 17b recognition
To check whether the purified gp120 was correctly folded, we first investigated its ability to interact with CD4. SPR experiments were conducted for that purpose, in which gp120 was flowed across a CD4 functionalized surface. Analysis of the resulting binding curves ( Fig. 2A) returned an affinity of 8 nM, in very good agreement with previously reported data using the same technique (38, 39) . To check whether our protein undergoes conformational changes upon CD4 binding, we monitored the binding of gp120 to mAb 17b, both in presence and in absence of soluble CD4 (sCD4). MAb 17b belongs to a group of antibodies, referred as CD4 induced (CD4i), which bind to gp120 only after CD4 engagement. It recognizes a surface that includes or is proximal to the bridging sheet, and thus competes with coreceptor binding (40) . In absence of sCD4, gp120 showed no or little binding to mAb 17b, indicating that in its CD4-unbound state the bridging sheet of gp120 remains unexposed or unfolded. Preincubation of gp120 with sCD4 dramatically increased binding to mAb 17b, indicating that sCD4 triggers the conformational changes that lead to the formation/exposure of the coreceptor binding site (Fig. 2B ). Taken together, these results provide evidence that the protein was properly folded and functional.
Mapping of heparin binding domains within wild type gp120
Although the importance of the V3 loop for binding to heparin is well established, additional HBDs have been suggested but not identified yet. We thus performed a global analysis of the interaction between gp120 and heparin using a method adapted from the "beads sequencing approach" that has been previously reported (37) . This approach was based on the capture of the protein of interest on heparin immobilized beads, the proteolytic digestion and the N-terminus sequencing of the peptides remaining attached to the heparinbeads. However, because in some experiments beads were washed throughout the system despite the filter and blocked the sequencing machine, the cross-linking, the proteolysis and the N-terminus sequencing were now performed in solution. In addition, this enabled the use of defined oligosaccharides (instead of commercial heparin), and the results described below have been obtained with both full length heparin and a heparin derived 12-mer (dp12), used as a model of the S domains that characterize heparan sulfate (41) . Carboxyl groups of soluble heparin (or dp12) were EDC/NHS-activated, reacted with gp120, then, formed protein/saccharide conjugates were submitted to proteolytic digestion. Peptides cross-linked to heparin were recovered by DEAE chromatography, and analyzed by Nterminal sequencing. As shown in Fig. 3 within HBD 2 and Lys 500 within HBD 3 were not detected, indicating that these were involved in the cross-linking with heparin, or dp12. The observation that a relatively small oligosaccharide (dp12) targets the same sequences and exactly returns the same results than full length heparin indicates that having a large number of anionic charge does not give rise to additional (non specific) binding, and supports the specificity of the assay (see (37) ).
HBD 1 is located in the second half of V1/V2 loop, 20 residues upstream the β3 strand that contributes, along with β2, β20 and β21 strands to the CD4 induced epitope. HBD 2 is at the N-terminus of the V3 loop and HBD 3 in the C-terminus of gp120 (C5 region). These data thus support the role of a motif within the V3 loop involved in heparin binding and in addition identified two other HBDs within the V2 loop and at the C-terminus that have not been reported yet.
Mutation of Arg
419
, Lys 421 and Lys 432 but not Lys 121 decrease gp120 binding to heparin in the presence of sCD4 Molecular modeling analysis, performed on a sCD4/gp120 complex revealed that a number of residues, located between the stems of the V1/V2 and V3 loops, form a cluster of positively charged residues organized as a possible HBD (33) . These residues belong to the four-stranded "bridging sheet" structure, induced and stabilized by CD4, which importantly contribute to coreceptor binding. This binding surface being clearly a potential target for therapeutic interventions, it was important to provide a better account of the residues possibly involved in heparin binding. In that aim, we generated mutant proteins in which each of the amino acids predicted to interact with heparin (Lys ) were changed for Ser residue. Analysis of their heparin binding abilities, using a Biacore based binding assay did not show large differences (Fig. 4 and supplemental data Fig. S1 ). This was expected, since in absence of CD4, the mutated residues are only partially exposed and/or not clustered. This is also consistent with the availability of the HBD 1 to 3 on the unliganded gp120 surface. Bound to sCD4, wild type gp120 displayed a strongly enhanced binding to heparin, demonstrating the importance of the bridging sheet, once exposed or folded, for heparin recognition. Similarly, gp120-K121S showed a large increase in heparin binding, indicating that yielded proteins that only displayed a modest increase in heparin binding, when bound to CD4 (Fig. 4 and supplemental data Fig. S1 ), thus strongly suggesting that each of these residues were involved in the interaction. These experiments were repeated on a heparan sulfate activated sensorchip, prepared as described (42) , and gave rise to similar results (data not shown).
Arg
419
, Lys 421 and Lys 432 within the CD4 induced epitope are involved in heparin binding A possible explanation of the above results would be that gp120 mutants became unable to expose the bridging sheet upon binding to CD4. To investigate this, we designed an assay in which we first measured the binding of gp120 to mAb 17b, in the presence of sCD4 (which reveals the exposition of the bridging sheet), and then analyzed the ability of heparin to compete with mAb 17b (which reflects the binding of heparin to the induced epitope). We observed ( Fig. 5 and supplemental data Fig.  S2 ) that none of the gp120 significantly bound to immobilized mAb 17b (30 to 60 RU). However, they all displayed a dramatic increase in binding, once complexed to CD4. This first point indicated that gp120 mutants, (as the wild type) were all able to expose a properly folded bridging sheet upon binding to CD4. We next investigated the ability of heparin to target this surface, by evaluating, as a read out, the extent to which heparin could compete with mAb 17b. These experiments showed that heparin (200 nM) almost fully inhibited the binding of the sCD4/gp120 complex to mAb 17b for both wild type gp120 and K121S mutant ( Fig. 5 and supplemental data Fig. S2 ). This indicates that heparin efficiently binds to mAb 17b epitope, even in the absence of Lys 121 and thus supports that this residue is not involved in heparin binding. In contrast, for the three other mutants, especially R419S and K421S, heparin only partially inhibited the gp120/mAb 17b interaction (Fig. 5) . Taken together, these data further demonstrated that a HBD is comprised within the CD4 induced epitope, in which the Arg 419 and Lys 421 play a major role, while Lys 121 is not involved.
DISCUSSION
Several studies reported a role for HS in HIV attachment onto both CD4 positive and negative cells. Up to now, this interaction has been mainly attributed to the gp120 V3 loop, although a number of evidence suggested that this particular domain does not fully recapitulate the binding activity of the protein.
To investigate in more detail the structural basis of this interaction, we recombinantly produced wild type and mutant gp120 using the baculovirus expression system. To increase production yields, the rate limiting natural leader sequence of gp120 was changed for that of the honeybee melittin (43) . In preliminary studies, the production of gp120 was analyzed using four different insect cell lines: Sf21, Sf9, High Five (HF) and Mimic Sf9 cells. Sf21 and Sf9 gave similar results in term of expression levels. HF cells allowed higher expression of the protein, but it migrated as a heterogeneous entity on SDS-PAGE. Finally, Mimic Sf9, a Sf9 derived insect cell line modified to stably express a variety of mammalian glycosyltransferases (44) , failed in our hands to express significant amounts of gp120. Sf21 cells were thus used throughout the study, and yielded to 25-30 mg of gp120 per liter of culture medium, from which a three purification step enabled us to routinely isolate 1 mg of pure and correctly refolded protein.
Characterization of gp120/HS interaction was then undertaken, first using a mapping strategy to identify HBDs. This method, which uses native proteins, is based on the formation of cross-linked complexes between the protein of interest and heparin-beads, the proteolytic digestion of these complexes, and the subsequent identification of the HBD containing peptides by N-terminus sequencing (37) . Since this method was developed, it has been used to analyze a number of other proteins, including Antithrombin III, PrP or Adam 12 (unpublished data) and successfully identified their HBDs. It is worth noting that for these proteins, as for those previously studied (37), non specific cross-linking was never observed in any of the experiments, despite the presence of a large number of putative coupling lysine residues in the tested proteins. The use of heparin-beads, rather than soluble heparin, facilitates the different washing steps. However, these commercial beads are restricted to heparin, and are thus not adapted to the analysis of specific heparin derived oligosaccharides or other glycosaminoglycans. In addition, beads were occasionally washed throughout the system despite the filter and blocked the sequencing machine. Here, we thus improved the method by performing the cross-linking, the proteolysis and the N-terminus sequencing in solution. To recover the peptide/heparin complexes, a purification step (DEAE column) was included in the protocol, between the proteolysis and the N-terminal sequencing. HIV-1 gp120 was analyzed with this method, using either full length heparin or a 12 mer heparin derived oligosaccharide. Both samples returned similar results, and consistently pointed out sequences including three crosslinked residues: Lys 168 , Lys 305 and Lys 500 . Lys 168 is within a small basic amino acid cluster RGKVQK (HBD 1; residues 166-171) located within the V2 loop. Lys 305 takes part of a typical basic stretch of amino acids, RKRIR (HBD 2; residues 304-308), at the very beginning of the V3 loop. Interestingly, a few residues upstream this sequence, Arg 298 was recently found to be involved in HS recognition (45) . Finally, Lys 500 defined a third cluster of basic amino acids, KAKRR (HBD 3; residues 500 to 504), at the C-terminal domain of the protein. In addition to these, we previous reported that several residues of the CD4 induced bridging sheet (amino acids 121, 419, 421 and 432) are clustered into a potential HBD and thus could also contribute to the binding (33) . We thus expressed gp120 in which these residues were mutated and found that three of them (419, 421 and 432) were actually involved in the interaction and thus constitute an additional binding domain (HBD 4). Interestingly, all of the four domains targeted by heparin are functionally important. HBD 1 is located at the N-terminus of the V2 loop, a domain of the protein that, along with the V3 loop, undergoes important structural changes following CD4 binding, resulting in the unmasking of the coreceptor binding site. The V3 loop, which structure has been recently solved in the context of the gp120 core (46) has a number of critical roles (see (47) for review). It comprises an immunodominant epitope, commonly known as the principal neutralization determinant (residues 308 to 322, therefore next to the HBD). It determines coreceptor usage (CCR5 or CXCR4), and thus has a major influence on viral tropism and pathogenicity. In particular, basic amino acid enrichment of V3 is typical of a viral phenotype shift from CCR5 to CXCR4 usage, and this correlates with HS binding ability (32) . Importantly, the V3 region also displays essential features for coreceptor binding. In particular, mutation of residues Arg 298 , Arg 306 and Arg
308
, present in HBD 2, strongly decrease the ability of gp120 to interact with CXCR4 (48, 49) . Regarding the C-terminal domain, it was reported that the replacement of all four basic amino acids of HBD 3 blocks the furin mediated processing of gp160 into gp120 and gp41 (50) suggesting a relationship between the KAKRR cluster and the furin cleavage sequence. It is worth noting that the furin cleavage site (REKR; amino acids 508 to 511) is located only 3 residues downstream the KAKRR sequence. It has just been reported that synthetic peptides spanning the gp120/gp41 junction are only poor furin substrates in absence of heparin, and addition of the polysaccharide importantly increases cleavage of these peptides (51) . It is thus tempting to propose that heparin binding to HBD 3, at least in the context of an isolated peptide, induces structural changes and better expose the furin cleave site. However, proteolytic cleavage of gp160, into gp120 and gp41 normally occurs intracellularly (52), while HS is present at the cell surface, thus the physiological significance of the above observations is not clear. Another possibility would be that these domains mediate virion attachment to cell surface HS, as it has already been shown for the furin protease cleavage sequence of the Sindbis virus (53) . Finally, HBD 4, only functional in the CD4 bound form of gp120, is included within the highly conserved coreceptor binding domain of the protein. One striking aspect of this domain is its basic nature, where seven basic amino acids are located within a relatively restricted surface (5) . It is worth noting that the N-terminal domains of both CCR5 and CXCR4 coreceptor feature a number of sulfotyrosines that contribute to gp120 binding and HIV-1 entry. Similarly, a number of antibodies, targeting the bridging sheet that connects the inner and the outer domain of the CD4 bound form of the glycoprotein (CD4i epitope) display sulfotyrosines in their antigen binding site (54) , supporting the present data. The binding of heparin with the CD4i region may thus mimic, to some extent, the interaction taking place with CD4i antibodies or the coreceptor N-terminal domain. Finally, it is worth noting that, 3 of the 4 heparin binding domains (HBD 1, 2 and 4) are located close to each others, at the proximity of, or within, the coreceptor binding site, and are collectively involved in the conformational changes induced upon interaction with CD4. Although the function of these interactions is not yet completely known, it is clear that these 3 HBDs are targets of interest. A number of polyanionic, heparin-like molecules, are currently evaluated as HIV microbicides (55) . In that context, the characterization of the different HBDs should help to better understand the activity of-or better designsuch polyanionic compounds. In particular, the finding that the coreceptor binding region directly interacts with heparin after CD4 binding is an argument for the engineering of a CD4 molecule, covalently linked to heparin like oligosaccharides, which would target both the coreceptor and the CD4 binding site.
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We thank Q. Sattentau and N. Thielens for their respective gift of plasmid pSVIII-env and pNT-Bac, and F. Véas for recombinant gp120 used as a standard in this study. Soluble CD4 was obtained through the NIH AIDS Research and Reference Reagent Program from Dr. Sai Iyer, and mAb 17b from the Centre for AIDS Reagent Program, NIBSC. This work was supported by the Agence Nationale de la Recherche sur le SIDA (ANRS), the Centre National de la Recherche scientifique (CNRS) and the Commisariat à l'Energie Atomique (CEA). Elodie Crublet is supported by a doctoral fellowship from the ANRS and Sidaction. Fig. 1 : Time-course expression and purification of gp120. (A) Sf21 cells were infected with gp120-baculoviruses. Samples were taken 0, 24, 48, 72, 96 and 120 h post-infection, analyzed on SDS-PAGE, then transferred to PVDF membrane for Western blotting. "St" stands for "standard" which corresponds to 100 ng of purified gp120. The wild type protein was purified from the culture medium of Sf21 infected cells in three steps as described in the Material and Methods section. Samples were analyzed by SDS-PAGE and Coomassie-blue staining, on which equivalent portions of the initial sample were loaded (B). Lane 1, sample purified from culture medium by cation exchange chromatography; lane 2, Wash-through from the Lentil-lectin resin column; lane 3, sample eluted from the Lentil-lectin affinity column; lane 4, gel filtration-purified sample. Mutants were purified using the same protocol. (C) Three µg of wild type or K121S, R419S, K421S and K432S purified protein were analyzed by SDS-PAGE, and revealed by Coomassie-blue staining. Molecular weight markers (in kilo Daltons) are indicated on the left of each panel. Binding response (RU)
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